Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.
Various types of experimental autoimmune encephalomyelitis (EAE) reflect some of the pathogenetic, clinical, and therapeutic features of the different forms of multiple sclerosis (MS), thereby, providing some, albeit limited, insight into the molecular and cellular basis of the human disease. Specific questions of MS therapy including the search for new therapeutic targets and strategies and their validation require investigations in different available EAE models. A survey is given of experimental therapeutic approaches that are currently under study with the most promising examples of monoclonal antibodies, gene therapy, stem cell transplantation and orally applied small molecular weight disease-modifying drugs. Reasons for therapy failure and adverse side-effects of some experimental trials are discussed. Precaution is advised, if results of new experimental approaches are translated into clinical practice.
Mix
Eilhard
E
University of Rostock, Department of Neurology, Gehlsheimer Str. 20, 18147 Rostock, Germany. eilhard.mix@med.uni-rostock.de
Meyer-Rienecker
Hans
H
Zettl
Uwe K
UK
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*
D007155:Immunologic Factors